Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase ActivityJack D. Scott, Michael W. Miller, Xing Dai et al.|Journal of Medicinal Chemistry|2017Cited by 147
The effect of LRRK2 loss-of-function variants in humansNicola Whiffin, Molly Schleicher, Irina M. Armean et al.|Nature Medicine|2020Cited by 113